Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting
20 Mai 2019 - 1:00PM
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced
that Dr. Patricia Keller, Senior Scientist at Constellation
Pharmaceuticals, presented a poster titled Targeting epigenetic
dysregulation in bladder cancer through inhibition of EZH2 at the
Bladder Cancer: Transforming the Field meeting of the American
Association for Cancer Research in Denver on May 19.
The poster discusses results of Constellation’s work with its
second-generation EZH2 inhibitor CPI-0209 in bladder cancer models,
exploring whether ARID1A mutation status affected responsiveness to
CPI-0209 treatment. ARID1A, a protein that is a key component
of the SWI/SNF chromatin remodeling complex, is mutated in about
25% of muscle-invasive bladder cancers.
Constellation used CPI-0209 in long-term phenotypic growth
assays in a panel of 21 bladder cancer cell lines, demonstrating
preferential treatment sensitivity that correlated with increased
cell death in cell lines harboring ARID1A mutations.
Transcriptional profiling after CPI-0209 treatment showed
widespread activation of EZH2 target gene expression. In vivo,
once-daily treatment with CPI-0209 in bladder cell-line derived
xenografts harboring ARID1A mutations produced dose-dependent tumor
growth inhibition and regression. Treatment with CPI-0209 and the
chemotherapeutic agent cisplatin demonstrated combinatorial effects
on cell viability in vitro and on tumor growth in vivo. The poster
can be viewed in the Investors & Media/Presentations section of
our website.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage
biopharmaceutical company developing novel therapeutics that
selectively modulate gene expression to address serious unmet
medical needs in patients with cancer. The Company has a deep
understanding of how epigenetic and chromatin modifications in
cancer cells and in the tumor and immune microenvironment play a
fundamental role in driving disease progression and drug
resistance. Constellation is driving development of the EZH2
inhibitors CPI-1205 and CPI-0209 for the treatment of metastatic
castration-resistant prostate cancer and other cancers as well as
the BET inhibitor CPI-0610 for the treatment of myelofibrosis. The
Company is also applying its broad research and development
capabilities to explore other novel targets that directly and
indirectly impact gene expression to fuel a sustainable pipeline of
innovative small-molecule product candidates.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve substantial risks and uncertainties, including
statements regarding the implications of preliminary clinical data,
the development status of the Company’s product candidates, the
Company’s plans for future data presentations, its anticipated
achievement of milestones, including determination of proof of
concept and its financial guidance regarding the period in which it
will have capital available to fund its operations. All
statements, other than statements of historical facts, contained in
this press release, including statements regarding the Company’s
strategy, future operations, future financial position, prospects,
plans and objectives of management, are forward-looking statements.
The words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in,
or implied by, such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks associated
with Constellation’s ability to: obtain and maintain necessary
approvals from the FDA and other regulatory authorities; continue
to advance its product candidates in clinical trials; whether
preliminary or interim results from a clinical trial will be
predictive of the final results of the trial; replicate in later
clinical trials positive results found in preclinical studies and
early-stage clinical trials of CPI-1205, CPI-0610 and its other
product candidates; advance the development of its product
candidates under the timelines it anticipates, or at all, in
current and future clinical trials; obtain, maintain or protect
intellectual property rights related to its product candidates;
manage expenses; and raise the substantial additional capital
needed to achieve its business objectives. For a discussion of
other risks and uncertainties, any of which could cause the
Company’s actual results to differ from those contained in the
forward-looking statements, see the “Risk Factors” section, as well
as discussions of potential risks, uncertainties, and other
important factors, in the Company’s most recent filings with the
Securities and Exchange Commission. In addition, the forward-
looking statements included in this press release represent the
Company’s views as of the date hereof and should not be relied upon
as representing the Company’s views as of any date subsequent to
the date hereof. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. CPI-1205, CPI-0610, CPI-0209,
and other product candidates are investigational in nature and have
not yet been approved by the FDA or other regulatory
authorities.
ContactRonald Aldridge Senior Director,
Investor RelationsConstellation Pharmaceuticals+1
617-714-0539ron.aldridge@constellationpharma.com
Lauren ArnoldMedia RelationsMacDougall Biomedical
Communications+1 781-235-3060larnold@macbiocom.com
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024